Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.75
Bid: 44.00
Ask: 45.50
Change: -0.40 (-0.88%)
Spread: 1.50 (3.409%)
Open: 45.50
High: 45.10
Low: 45.10
Prev. Close: 45.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

Wed, 24th Feb 2021 11:45

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Avacta Group PLC - AIM-listed developer of Affimer biotherapeutics and reagents - Proceeding to full clinical valuation for its Covid-19 test to support a CE Mark, with a possible commercial launch of the test for professional use near the end of the first quarter of 2021. Chief Executive Alastair Smith says Avacta is close to fully establishing its supply chain for scalable manufacture of test kits and "making timely progress in instituting a quality management system to support the required ISO13485 accreditation for medical devices". The AffiDX SARS-CoV-2 lateral flow rapid antigen test is, as far as Avacta is aware, "the most sensitive S1 spike lateral flow test available". December 31 cash position GBP28 million, a little higher than market forecasts.

----------

Gooch & Housego PLC - Somerset-based optical components and systems maker - Notes improved levels of demand across industrial laser sector during the first four months of its financial year ending September 2021. This includes, in line with previously reported trends, continuing high levels of demand for fibre optics, hi-reliability fibre couplers as well as its Aerospace & Defence capabilities. Also sees strong growth from Life sciences. Recovering in industrial lasers led by Asian markets, though US and European markets now also showing "encouraging trends" while 5G rollout "has fuelled demand led growth, building on the previously reported recovery in semiconductors". A&D order book robust. Medial diagnostics demonstrating good growth with improves levels of demand for medical laser products, previously hurt by reduced non-Covid-19 procedures in financial 2020. Cash generation robust, net debt further shrinks in first four months of financial year despite payment of final earn out associated with an acquisition. January 31 order book GBP95.0 million, a little higher than the previous year's GBP94.1 million. Streamlining manufacturing sites, with all product lines at Glenrothes, Scotland facility transferred to new UK Precision Optics hub in Ilminster and Glenrothes site now closed. Outsourcing of Acousto Optic products from Ilminster to Asian contract manufacturer "progressing well" and set to complete by financial year end. Begins transferring production from St Asaph, Wales facility to Ilminster Precision Optics hub. Optical systems engineering and design centre to be retained in St Asaph. Target completion of both projects by current financial year end.

----------

Proactis Holdings PLC- Wetherby-based cash management software company - Expects to post a drop in revenue for the six months ended January 31 to GBP23.7 million from GBP24.5 million but with higher adjusted earnings before interest, tax, depreciation, and amortisation of GBP6.2 million versus GBP5.6 million the year before. Explains that its operating margins have improved after it restructures its management team and operating costs base. Says net bank debt at the end of January was GBP39.7 million, up from GBP37.1 million on July 31. Explains that its position has been hurt by a reduction in cash levels from its outsourced sourcing business as a consequence of lower trading volumes due to Covid-19 plus cash flow and upfront costs of the restructure. Expects to post a half-year performance in line with board expectations.

----------

Echo Energy PLC - Latin America focused upstream oil and gas company - Agrees, along with Santa Cruz Sur partners, to capital expenditure for upgrading and debottlenecking the existing liquids pipelines in the Santa Cruz Sur assets, located in onshore Argentina. This will accelerate a return to full oil production and bring remaining volumes, previously shut in the second quarter of 2020, back online. This follows an increase in demand, which resulted in improved pricing and more frequent oil sales. Pipeline upgrades will also grant additional capacity for production enhancement product in the future, which have been identified. Capital expenditure, net to Echo's 70% working interest in Santa Cruz Sur, will be around USD175,000 and will be injected by Echo to replace and upgrade parts of the infrastructure - mostly in the Chorillos, Campo Molino and Cerro Convento fields. Installation is expected to take around 45 days with 10 upgrade projects to be completed, upgrading a total of around 23 kilometres of pipeline and restoring gross daily liquids production to between 480 barrels of oil per day and 600 bopd, or 336bopd to 420 bopd net to Echo. In 2020, total cumulative production net to Echo from Santa Cruz Sur was 720,000 boe. From January

----------

Alba Mineral Resources PLC- mineral exploration and development company with assets in Greenland and the UK - Says it has planned the next phase of regional exploration for the Dolgellau gold exploration project in north Wales. The next phase of work over the field involves stream sediment sampling, which is designed to identify hard-rock gold sources upstream of sampling locations. This will be the first field work to take place over Alba's Gwynfynydd exploration licence area since the licence was warded in November 2020. Chair George Frangeskides, says: "For the first time, we will be expanding our regional exploration programme to cover our recently granted Gwynfynydd exploration licence. We are very optimistic about the prospects for finding new gold deposits in the Dolgellau gold field."

----------

Angling Direct PLC - Norwich, Norfolk-based fishing tackle and equipment retailer - Expects to post a 27% revenue increase for its financial year ended January 31 to GBP67.6 million from GBP53.2 million the year before despite closure of its retail stores and only being able to operate on a "call & collect" basis under lockdown rules. This growth results from online sales, up 40% to GBP35.3 million from GBP25.2 million with. Total store sales, including call & collect, rose 16% to GBP32.3 million from GBP27.9 million with the total number of stores increasing to 38 on January 31 from 34 the prior year and new stores contributed GBP2.2 million in sales. Forecasts pre IFRS-16 Ebitda of at least GP3.8 million for financial 2021 versus a GBP500,000 loss year-on-year. Cash position at January end GBP15.0 million, sharply rising from GBP5.9 million the year before. Not providing guidance for financial 2022 until full extent of Covid-19 disruption is known.

----------

IronRidge Resources Ltd - Australia-based minerals exploration company - Drilling progressing well at the Ewoyaa lithium project in Ghana, with around 4,1000 in 40 reverse circulation holes completed so far. Says visible coarse spodumene mineralisation has been observed in 36 holes to date, with maximum reported pegmatite internals up to 36 metres and approximating true width. Spodumene mineralisation has been observed in most pegmatite targets tested, with good continuity up to 300 metres along strike and down dip. Average pegmatite widths between 10 and 15 metres. So far, three of the seven pegmatite target zones have been drill tested and drilling is ongoing, with assays pending. Chief Executive Vincent Mascolo says: "This drilling programme is a key part of our work towards expanding the resource base on what is widely considered to be an industry-leading asset. We are now evaluating options to fast track the project to production to take advantage of the increasing demand for lithium and its role in the future growth of stored energy initiatives."

----------

By Anna Farley; annafarley@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
19 Dec 2023 10:24

Avacta appoints new chief business officer

(Sharecast News) - Oncology drugs and diagnostics specialist Avacta Group announced the appointment of Dr Simon Bennett as the chief business officer of its therapeutics division on Tuesday.

Read more
19 Dec 2023 09:57

IN BRIEF: Avacta taps biopharma veteran as Therapeutics business chief

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Hires Simon Bennett as chief business officer of Therapeutics division. Says Bennett has over 26 years of commercial experience in the biopharma industry and has "worked with" various large and mid-sized companies like Bristol-Myers Squibb Co and Menarini Group.

Read more
13 Dec 2023 11:49

Avacta says study shows cancer treatment AVA6000 working as planned

(Alliance News) - Avacta Group PLC on Wednesday celebrated strong results from its latest cancer-targeting study, which showed the release of a chemotherapy to the tumour as intended.

Read more
13 Dec 2023 07:46

Avacta hails "encouraging" clinical data from cancer-targeting study

(Sharecast News) - Oncology drugs group Avacta has announced positive results from its lead pre|CISION programme, AVA6000, which it says has the potential to be "truly remarkable".

Read more
28 Sep 2023 11:08

IN BRIEF: Avacta loss widens on cost rise but clinical tests positive

Avacta Group PLC - Wetherby, England-based life sciences company that develops targeted oncology drugs and diagnostics - Pretax loss widens to GBP12.8 million in the six months that ended June 30 from GBP9.7 million a year before. Revenue doubles to GBP11.9 million from GBP5.5 million, but selling, general and administrative expenses near double as well, to GBP8.6 million from GBP4.7 million. Research costs are steady at GBP6.0 million. Has GBP26.0 million cash, up from GBP17.0 million a year before, though down from GBP41.8 million on December 31. Highlights success of AVA6000, a chemotherapy drug for cancer patients, in a Phase 1a clinical study. Avacta aims to complete a dose escalation safety study and provide results during the fourth quarter.

Read more
28 Sep 2023 07:57

Avacta reports higher losses in first half

(Sharecast News) - Cancer treatments and diagnostics group Avacta reported higher losses in the first half despite a doubling of revenues.

Read more
21 Sep 2023 15:48

UK earnings, trading statements calendar - next 7 days

Friday 22 September 
Ascential PLCHalf Year Results
Ergomed PLCHalf Year Results
First Tin PLCHalf Year Results
t42 IoT Tracking Solutions PLCHalf Year Results
t42 IoT Tracking Solutions PLCTrading Statement
Monday 25 September 
Alphawave IP Group PLCHalf Year Results
Devolver Digital IncHalf Year Results
Dialight PLCHalf Year Results
Getech Group PLCHalf Year Results
Ondine Biomedical IncHalf Year Results
Real Estate Investors PLCHalf Year Results
SpaceandPeople PLCHalf Year Results
Spectra Systems CorpHalf Year Results
Transense Technologies PLCFull Year Results
Venture Life Group PLCHalf Year Results
Wilmington PLCFull Year Results
Tuesday 26 September 
Alliance Pharma PLCHalf Year Results
AG Barr PLCHalf Year Results
Animalcare Group PLCHalf Year Results
Asos PLCTrading Statement
Boku IncHalf Year Results
Card Factory PLCHalf Year Results
Cambridge Cognition Holdings PLCHalf Year Results
Close Brothers Group PLCFull Year Results
Diaceutics PLCHalf Year Results
DigitalBox PLCHalf Year Results
Dillistone Group PLCHalf Year Results
EKF Diagnostics Holdings PLCHalf Year Results
Ferguson PLCFull Year Results
Finsbury Food Group PLCFull Year Results
IQGeo Group PLCHalf Year Results
Learning Technologies Group PLCHalf Year Results
LifeSafe Holdings PLCHalf Year Results
Mission Group PLCHalf Year Results
Mortgage Advice Bureau Holdings PLCHalf Year Results
NAHL Group PLCHalf Year Results
Next 15 Group PLCHalf Year Results
Newmark Security PLCFull Year Results
NIOX Group PLCHalf Year Results
Origin Enterprises PLCFull Year Results
PZ Cussons PLCFull Year Results
Safestay PLCHalf Year Results
Smiths Group PLCFull Year Results
Time Finance PLCFull Year Results
tinyBuild IncHalf Year Results
Wentworth Resources PLCHalf Year Results
Yu Group PLCHalf Year Results
Wednesday 27 September 
Amicorp FS (UK) PLCHalf Year Results
Aquila European Renewables PLCHalf Year Results
Arix Bioscience PLCHalf Year Results
Avingtrans PLCFull Year Results
Bens Creek Group PLCFull Year Results
Biome Technologies PLCHalf Year Results
BioPharma Credit PLCHalf Year Results
Chapel Down Group PLCHalf Year Results
Everyman Media Group PLCHalf Year Results
Fadel Partners IncHalf Year Results
NCC Group PLCFull Year Results
Old Mutual LtdHalf Year Results
Pantheon Infrastructure PLCHalf Year Results
Pendragon PLCFull Year Results
Plant Health Care PLCHalf Year Results
Safestyle UK PLCHalf Year Results
Saga PLCHalf Year Results
Skillcast Group PLCHalf Year Results
Surface Transforms PLCHalf Year Results
Xeros Technology Group PLCHalf Year Results
Zinc Media Group PLCHalf Year Results
Thursday 28 September 
Atlantic Lithium LtdFull Year Results
Avacta Group PLCHalf Year Results
Avation PLCFull Year Results
Celadon Pharmaceuticals PLCHalf Year Results
Ceres Power Holdings PLCHalf Year Results
Dar Global PLCHalf Year Results
eEnergy Group PLCFull Year Results
HSS Hire Group PLCHalf Year Results
Microlise Group PLCFull Year Results
Novacyt SAHalf Year Results
Phoenix Spree Deutschland LtdHalf Year Results
RBG Holdings PLCHalf Year Results
Shield Therapeutics PLCHalf Year Results
Silver Bullet Data Services Group PLCHalf Year Results
Trellus Health PLCHalf Year Results
Trinity Exploration & Production PLCHalf Year Results
XLMedia PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
20 Sep 2023 14:37

TRADING UPDATES: Capital inks contract; Lansdowne becomes cash shell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Sep 2023 11:57

Avacta brings in clinical consultant as it hunts for permanent CMO

(Sharecast News) - Oncology-focussed life science company Avacta Group announced a new consultancy pact with Dr Christina Coughlin on Tuesday.

Read more
19 Sep 2023 13:39

Avacta upbeat on fresh data from chemotherapy trial

(Sharecast News) - Life sciences company Avacta Group announced the successful completion of its sixth dose escalation cohort in the ALS-6000-101 phase one clinical trial on Tuesday, assessing the safety and tolerability of the drug, AVA6000.

Read more
19 Sep 2023 13:36

Avacta notes "excellent" safety profile for prospective sarcoma drug

(Alliance News) - Avacta Group PLC on Tuesday said it successfully completed the sixth dose escalation of the ALS-6000-101 phase 1 clinical trial, in which its AVA6000 soft tissue sarcoma treatment demonstrated an "excellent" safety profile.

Read more
21 Jul 2023 16:00

IN BRIEF: Avacta Group issues 3.8 million shares to make repayment

Avacta Group PLC - Wetherby, England-based life sciences company developing targeted oncology drugs and diagnostics - Issues 3.8 million new shares of 10 pence each to settle quarterly principal of GBP2.6 million and interest repayment of GBP760,000. After settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by GBP2.6 million to GBP44.2 million.

Read more
21 Jun 2023 15:43

UK shareholder meetings calendar - next 7 days

Thursday 22 June 
Alphawave IP Group PLCAGM
Angling Direct PLCAGM
Anglo Asian Mining PLCAGM
boohoo Group PLCAGM
Braime Group PLCAGM
Card Factory PLCAGM
Ergomed PLCAGM
Falcon Oil & Gas LtdAGM
Futura Medical PLCAGM
Good Energy Group PLCAGM
Grand Vision Media Holdings PLCAGM
Longboat Energy PLCAGM
MaxRets Ventures PLCAGM
Pathfinder Minerals PLCAGM
RBG Holdings PLCAGM
Robinson PLCAGM
Sanderson Design Group PLCAGM
Team17 Group PLCAGM
Trellus Health PLCAGM
Whitbread PLCAGM
Friday 23 June 
Cadogan Petroleum PLCAGM
Mears Group PLCAGM
Non-Standard Finance PLCAGM
Ocean Harvest Technology Group PLCAGM
Oxford Biomedica PLCAGM
Pelatro PLCAGM
Petrofac LtdAGM
Princess Private Equity Holding LtdAGM
Rathbones Group PLCGM re agreement regarding all-share combination with Invested Wealth & Investment Ltd
Supply@Me Capital PLCGM re open offer warrant holders
Vietnam Enterprise Investments LtdAGM
VPC Specialty Lending Investments PLCAGM
Monday 26 June 
Aterian PLCAGM
Capricorn Energy PLCAGM
Corre Energy BVAGM
Facilities by ADF PLCAGM
Lexington Gold LtdSGM re proposed acquisition of White Rivers Exploration Ltd
LifeSafe Holdings PLCAGM
Premier African Minerals LtdAGM
Vast Resources PLCGM re issuing new share capital
Volvere PLCAGM
Tuesday 27 June 
Acuity RM Group PLCAGM
Comptoir Group PLCAGM
Creo Medical Group PLCAGM
First Tin PLCAGM
Forward Partners Group PLCAGM
Galantas Gold CorpAGM
Gemfields Group LtdAGM
Golden Prospect Precious Metals LtdAGM
Hamak Gold LtdAGM
ICG Enterprise Trust PLCAGM
Impellam Group PLCAGM
India Capital Growth Fund LtdAGM
Inspiration Healthcare Group PLCAGM
Instem PLCAGM
JD Sports Fashion PLCAGM
Kingfisher PLCAGM
Mercantile Ports & Logistics LtdGM re equity fundraising
Mobile Tornado Group PLCAGM
Revolution Beauty Group PLCAGM
Scottish Mortgage Investment Trust PLCAGM
Serabi Gold PLCAGM
Sondrel Holdings PLCAGM
Surface Transforms PLCAGM
Surgical Innovations Group PLCAGM
Trinity Exploration & Production PLCAGM
Wednesday 28 June 
Atalaya Mining PLCAGM
Avacta Group PLCAGM
Boku IncAGM
Cambridge Cognition Holdings PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Cobra Resources PLCAGM
Cora Gold LtdAGM
Dial Square Investments PLCAGM
Itaconix PLCAGM
NB Distressed Debt Investment Fund LtdAGM
Panthera Resources PLCGM re directors’ authority to allot shares
Phoenix Spree Deutschland LtdAGM
Pineapple Power Corp PLCAGM
Polarean Imaging PLCAGM
RA International Group PLCAGM
Schroder European Real Estate Investment Trust PLCAGM
Shield Therapeutics PLCAGM
St Mark Homes PLCAGM
Star Phoenix Group LtdAGM
ValiRx PLCAGM
Velocys PLCAGM
Vertu Motors PLCAGM
Warpaint London PLCAGM
Westminster Group PLCAGM
Zenova Group PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
21 Jun 2023 13:53

Avacta completes fifth dose escalation in chemotherapy trial

(Sharecast News) - Life sciences company Avacta announced the successful completion of the fifth dose escalation cohort in the phase 1 clinical trial for AVA6000 on Wednesday.

Read more
21 Jun 2023 09:58

Avacta says AVA6000 fifth dose escalation results "very favourable"

(Alliance News) - Avacta Group PLC on Wednesday said it has completed the fifth dose escalation cohort in its phase 1 clinical study of AVA6000.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.